Trials / Conditions / Recurrent Mixed Phenotype Acute Leukemia

Recurrent Mixed Phenotype Acute Leukemia

11 registered clinical trials studyying Recurrent Mixed Phenotype Acute Leukemia — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leuke NCT05761171	Children's Oncology Group	Phase 2
Active Not Recruiting	Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu NCT05146739	National Cancer Institute (NCI)	Phase 1
Withdrawn	A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Tr NCT05320380	Children's Oncology Group	Phase 1 / Phase 2
Recruiting	Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed NCT04872790	OHSU Knight Cancer Institute	Phase 1
Recruiting	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921	Fred Hutchinson Cancer Center	Phase 1
Terminated	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refracto NCT02879695	National Cancer Institute (NCI)	Phase 1
Recruiting	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Di NCT02135874	M.D. Anderson Cancer Center	Phase 2